|
| | Publication Year | Title | Author(s) |
| 1 | 22-Sep-2023 | Durable response to combination immunotherapy using nivolumab and ipilimumab in metastatic succinate dehydrogenase (SDH)-deficient gastrointestinal stroma tumour. | Klein, Oliver ; Palmer, Jodie ; Behren, Andreas; Cebon, Jonathan S ; Kee, Damien |
| 2 | 1-Apr-2023 | Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers? | Klein, Oliver ; Kee, Damien ; Nagrial, Adnan; Markman, Ben; Underhill, Craig; Michael, Michael; Behren, Andreas; Palmer, Jodie ; Tebbutt, Niall C ; Carlino, Matteo S; Cebon, Jonathan S |
| 3 | Feb-2022 | Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. | Goldinger, Simone M; Buder-Bakhaya, Kristina; Lo, Serigne N; Forschner, Andrea; McKean, Meredith; Zimmer, Lisa; Khoo, Chloe; Dummer, Reinhard; Eroglu, Zeynep; Buchbinder, Elizabeth I; Ascierto, Paolo A; Gutzmer, Ralf; Rozeman, Elisa A; Hoeller, Christoph; Johnson, Douglas B; Gesierich, Anja; Kölblinger, Peter; Bennannoune, Naima; Cohen, Justine V; Kähler, Katharina C; Wilson, Melissa A; Cebon, Jonathan S ; Atkinson, Victoria; Smith, Jessica L; Michielin, Olivier; Long, Georgina V; Hassel, Jessica C; Weide, Benjamin; Haydu, Lauren E; Schadendorf, Dirk; McArthur, Grant; Ott, Patrick A; Blank, Christian; Robert, Caroline; Sullivan, Ryan; Hauschild, Axel; Carlino, Matteo S; Garbe, Claus; Davies, Michael A; Menzies, Alexander M |
| 4 | Nov-2021 | Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial. | Klein, Oliver ; Kee, Damien ; Gao, Bo; Markman, Ben; da Gama Duarte, Jessica; Quigley, Luke; Jackett, Louise A ; Linklater, Richelle; Strickland, Andrew; Scott, Clare; Mileshkin, Linda; Palmer, Jodie ; Carlino, Matteo; Behren, Andreas; Cebon, Jonathan S |
| 5 | 1-Jul-2021 | Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. | Long, Georgina V; Robert, Caroline; Butler, Marcus O; Couture, Felix; Carlino, Matteo S; O'Day, Steven; Atkinson, Victoria; Cebon, Jonathan S ; Brown, Michael P; Dalle, Stephane; Hill, Andrew G; Gibney, Geoffrey T; McCune, Steven; Menzies, Alexander M; Niu, Cuizhen; Ibrahim, Nageatte; Homet Moreno, Blanca; Diab, Adi |
| 6 | Jul-2021 | Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. | Jacquelot, Nicolas; Seillet, Cyril; Wang, Minyu; Pizzolla, Angela; Liao, Yang; Hediyeh-Zadeh, Soroor; Grisaru-Tal, Sharon; Louis, Cynthia; Huang, Qiutong; Schreuder, Jaring; Souza-Fonseca-Guimaraes, Fernando; de Graaf, Carolyn A; Thia, Kevin; Macdonald, Sean; Camilleri, Mary; Luong, Kylie; Zhang, Shengbo; Chopin, Michael; Molden-Hauer, Tristan; Nutt, Stephen L; Umansky, Viktor; Ciric, Bogoljub; Groom, Joanna R; Foster, Paul S; Hansbro, Philip M; McKenzie, Andrew N J; Gray, Daniel H D; Behren, Andreas; Cebon, Jonathan S ; Vivier, Eric; Wicks, Ian P; Trapani, Joseph A; Munitz, Ariel; Davis, Melissa J; Shi, Wei; Neeson, Paul J; Belz, Gabrielle T |
| 7 | 15-Jun-2021 | Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. | Arulananda, Surein; O'Brien, Megan; Evangelista, Marco; Harris, Tiffany J ; Steinohrt, Nikita S; Jenkins, Laura J; Walkiewicz, Marzena; O'Donoghue, Robert J J; Poh, Ashleigh R; Thapa, Bibhusal ; Williams, David S ; Leong, Trishe; Mariadason, John M ; Li, Xia; Cebon, Jonathan S ; Lee, Erinna F; John, Thomas ; Fairlie, Walter Douglas |
| 88 | 9-Jun-2021 | PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma. | Parakh, Sagun ; Musafer, Ashan; Paessler, Sabrina; Witkowski, Tom ; Suen, Connie S N Li Wai; Tutuka, Candani S A; Carlino, Matteo S; Menzies, Alexander M; Scolyer, Richard A; Cebon, Jonathan S ; Dobrovic, Alexander ; Long, Georgina V; Klein, Oliver ; Behren, Andreas |
| 89 | 28-May-2021 | A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. | Arulananda, Surein; O'Brien, Megan; Evangelista, Marco; Jenkins, Laura J; Poh, Ashleigh R; Walkiewicz, Marzena; Leong, Trishe; Mariadason, John M ; Cebon, Jonathan S ; Balachander, Srividya B; Cidado, Justin R; Lee, Erinna F; John, Thomas ; Fairlie, Walter Douglas |
| 90 | 29-Apr-2021 | Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy. | Klein, Oliver ; Kee, Damien ; Markman, Ben; Carlino, Matteo S; Underhill, Craig; Palmer, Jodie ; Power, Daniel; Cebon, Jonathan S ; Behren, Andreas |
| 91 | 12-Apr-2021 | Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538. | Klein, Oliver ; Senko, Clare ; Carlino, Matteo S; Markman, Ben; Jackett, Louise A ; Gao, Bo; Lum, Caroline; Kee, Damien ; Behren, Andreas; Palmer, Jodie ; Cebon, Jonathan S |
| 92 | 9-Apr-2021 | Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses. | Da Gama Duarte, Jessica; Woods, Katherine; Quigley, Luke T; Deceneux, Cyril; Tutuka, Candani; Witkowski, Tom ; Ostrouska, Simone; Hudson, Chris; Tsao, Simon Chang-Hao; Pasam, Anupama; Dobrovic, Alexander ; Blackburn, Jonathan M; Cebon, Jonathan S ; Behren, Andreas |
| 93 | Jan-2021 | Migratory cues controlling B-lymphocyte trafficking in human lymph nodes. | Park, Saem Mul; Brooks, Anna Es; Chen, Chun-Jen J; Sheppard, Hilary M; Loef, Evert Jan; McIntosh, Julie D; Angel, Catherine E; Mansell, Claudia J; Bartlett, Adam; Cebon, Jonathan S ; Birch, Nigel P; Dunbar, P Rod |
| 94 | 31-Oct-2020 | BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. | Arulananda, Surein; O'Brien, Megan; Evangelista, Marco; Harris, Tiffany J ; Steinohrt, Nikita S; Jenkins, Laura J; Walkiewicz, Marzena; O'Donoghue, Robert J J; Poh, Ashleigh R; Thapa, Bibhusal ; Williams, David S ; Leong, Trishe; Mariadason, John M ; Li, Xia; Cebon, Jonathan S ; Lee, Erinna F; John, Thomas ; Fairlie, Walter Douglas |
| 95 | 1-Oct-2020 | Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. | Carlino, Matteo S; Menzies, Alexander M; Atkinson, Victoria; Cebon, Jonathan S ; Jameson, Michael B; Fitzharris, Bernard M; McNeil, Catriona M; Hill, Andrew G; Ribas, Antoni; Atkins, Michael B; Thompson, John A; Hwu, Wen-Jen; Hodi, F Stephen; Guminski, Alexander D; Kefford, Richard; Wu, Haiyan; Ibrahim, Nageatte; Homet Moreno, Blanca; Long, Georgina V |
| 96 | 16-Sep-2020 | Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma. | Faridi, Pouya; Woods, Katherine; Ostrouska, Simone; Deceneux, Cyril; Aranha, Ritchlynn; Duscharla, Divya; Wong, Stephen Q; Chen, Weisan; Ramarathinam, Sri H; Lim Kam Sian, Terry C C; Croft, Nathan P; Li, Chen; Ayala, Rochelle; Cebon, Jonathan S ; Purcell, Anthony W; Schittenhelm, Ralf B; Behren, Andreas |
| 97 | 7-Sep-2020 | Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report. | Hultin, Sebastian; Nahar, Kazi; Menzies, Alexander M; Long, Georgina V; Fernando, Suran L; Atkinson, Victoria; Cebon, Jonathan S ; Wong, Muh Geot |
| 98 | 1-Sep-2020 | Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial. | Klein, Oliver ; Kee, Damien ; Nagrial, Adnan; Markman, Ben; Underhill, Craig; Michael, Michael; Jackett, Louise A ; Lum, Caroline; Behren, Andreas; Palmer, Jodie ; Tebbutt, Niall C ; Carlino, Matteo S; Cebon, Jonathan S |
| 99 | Sep-2020 | Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers. | Klein, Oliver ; Kee, Damien ; Markman, Ben; Michael, Michael; Underhill, Craig; Carlino, Matteo S; Jackett, Louise A ; Lum, Caroline; Scott, Clare; Nagrial, Adnan; Behren, Andreas; So, Jane Y; Palmer, Jodie ; Cebon, Jonathan S |
| 100 | Jul-2020 | Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells. | Masterman, Kelly-Anne; Haigh, Oscar L; Tullett, Kirsteen M; Leal-Rojas, Ingrid M; Walpole, Carina; Pearson, Frances E; Cebon, Jonathan S ; Schmidt, Christopher; O'Brien, Liam; Rosendahl, Nikita; Daraj, Ghazal; Caminschi, Irina; Gschweng, Eric H; Hollis, Roger P; Kohn, Donald B; Lahoud, Mireille H; Radford, Kristen J |
Loading...
2
0
20
0
false
0000-0002-3898-950x